Comparison Chart Fate Therapeutics, Inc.

Stocks

FATE

US31189P1021

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:40:48 2026-11-10 EST			5-day change	1st Jan Change
1.930 ^USD	-0.52%		-3.48%	+97.44%

11-06	BofA Securities Adjusts Fate Therapeutics Price Target to $2.50 From $2.20	MT
11-05	Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	FATE THERAPEUTICS, INC.	Bio Therapeutic Drugs	+5.72%	-3.48%	+97.44%	+81.31%	-96.82%	232M